Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen
Current Oncology · 24.07.2024 · 31 (8) · 4165-4177
DOI: 10.3390/curroncol31080311 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 24.07.2024. Verfasst von Omar Tayara und 6 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Urology, Centre of Postgraduate Medical Education, 02-511 Warsaw, Poland. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron-Emission Tomography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer represents a significant public health challenge, with its management requiring precise diagnostic and prognostic tools. Prostate-specific membrane antigen (PSMA), a cell surface enzyme overexpressed in prostate cancer cells, has emerged as a pivotal biomarker. PSMA’s ability to increase the sensitivity of PET imaging has revolutionized its application in the clinical management of prostate cancer. The advancements in PET-PSMA imaging technologies and methodologies, including the development of PSMA-targeted radiotracers and optimized imaging protocols, led to diagnostic accuracy and clinical utility across different stages of prostate cancer. This highlights its superiority in staging and its comparative effectiveness against conventional imaging modalities. This paper analyzes the impact of PET-PSMA on prostate cancer management, discussing the existing challenges and suggesting future research directions. The integration of recent studies and reviews underscores the evolving understanding of PET-PSMA imaging, marking its significant but still expanding role in clinical practice. This comprehensive review serves as a crucial resource for clinicians and researchers involved in the multifaceted domains of prostate cancer diagnosis, treatment, and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Second Department of Urology, Centre of Postgraduate Medical Education, 02-511 Warsaw, Poland.
- Department of Nuclear Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
- Department of Methodology Laboratory, Centre for Preclinical Research, Medical University of Warsaw, 02-091 Warsaw, Poland.
ORCID-Profile: Omar Tayara, Sławomir Poletajew, Jolanta Kunikowska, Kacper Pełka, Piotr Kryst, Łukasz Nyk
Zitieren
APA
Tayara, O., Poletajew, S., Malewski, W., Kunikowska, J., Pełka, K., Kryst, P., & Nyk, Ł. (2024). Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen. Current Oncology, 31(8), 4165-4177. https://doi.org/10.3390/curroncol31080311
Vancouver
Tayara O, Poletajew S, Malewski W, Kunikowska J, Pełka K, Kryst P, et al. Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen. Current Oncology. 2024;31(8):4165-4177. doi:10.3390/curroncol31080311
BibTeX
@article{Tayara2024,
author = {Tayara, Omar and Poletajew, Sławomir and Malewski, Wojciech and Kunikowska, Jolanta and Pełka, Kacper and Kryst, Piotr and Nyk, Łukasz},
title = {Prostate-Specific Membrane Antigen Expression in Patients with Primary Prostate Cancer: Diagnostic and Prognostic Value in Positron Emission Tomography-Prostate-Specific Membrane Antigen},
journal = {Current Oncology},
year = {2024},
volume = {31},
number = {8},
pages = {4165--4177},
doi = {10.3390/curroncol31080311}
}
EUVIMED